Evotec Secures $9.9 Million in Gates Foundation Grants to Advance Next-Generation Tuberculosis Therapies
核心洞察
Evotec SE received two new grants totaling $9.9 million from the Gates Foundation (搜索) to advance tuberculosis (搜索) drug discovery and development over 24-25 months.
The funding will support AI-enabled discovery of novel small molecule TB (搜索) candidates and nonclinical evaluation of next-generation drug combinations, including Long Acting Injectables (搜索).
The grants aim to address critical TB (搜索) treatment challenges, with 10.7 million new cases and 1.23 million deaths reported in 2024 despite existing curable treatments.
Evotec SE announced it has received two grants from the Gates Foundation (搜索) totaling $9.9 million to advance tuberculosis (搜索) drug discovery and development, marking the company's continued commitment to addressing one of the world's most persistent infectious disease challenges. The new funding, comprising $4.9 million over 25 months and $5 million over 24 months, follows four previous TB (搜索) grants from the foundation.
The grants will expand Evotec's pipeline of novel TB (搜索) drug candidates and advance promising combinations toward clinical evaluation, with the ultimate goal of developing a universal, shorter, safer and simpler TB drug regimen. Despite tuberculosis (搜索) being curable with existing antibiotics (搜索), current treatments remain long, complex and difficult to complete, particularly for drug-resistant forms of the disease, leading to treatment failures.
AI-Driven Drug Discovery Initiative
The first grant supports Evotec's discovery efforts to advance a portfolio of novel small molecules (搜索) with the potential to treat all TB (搜索) patients. The company will combine its advanced AI-enabled drug discovery platform with deep TB drug discovery expertise to accelerate time to candidate selection and increase the likelihood of success. This approach aims to contribute to the development of improved treatment options that address current therapeutic limitations.
Next-Generation Drug Combinations
The second grant enables nonclinical characterization of next-generation TB (搜索) drug combinations proposed for late-stage clinical trials, including those with potential for delivery as Long Acting Injectables (搜索). These Long Acting Injectables represent a potentially transformative innovation in TB therapy, offering the possibility of simplified dosing regimens that could improve patient compliance and treatment outcomes.
Using its cutting-edge translational platforms, Evotec will generate critical data on pharmacokinetics, efficacy and resistance potential to inform optimal development pathways and de-risk progression to clinical testing. This comprehensive evaluation approach is designed to identify the combinations most likely to succeed in clinical trials.
Addressing Global TB Burden
Tuberculosis (搜索) continues to impose a substantial global health burden, with an estimated 10.7 million new cases and 1.23 million deaths reported in 2024. The disease, caused by Mycobacterium tuberculosis (搜索) bacteria, primarily affects the lungs but can also impact other organs. Persistent challenges including drug resistance and complex, burdensome treatment regimens highlight the urgent need for improved diagnostics, shorter and safer therapies, and sustained investment in innovation.
Dr. Cord Dohrmann, Chief Scientific Officer of Evotec, emphasized the importance of the foundation's continued support: "Effective TB (搜索) drug development requires both a robust pipeline of novel candidates and rigorous translational evaluation to identify the combinations most likely to succeed in the clinic. These grants empower us to leverage our integrated AI-driven discovery and translational platforms to identify and advance the most promising candidates and combinations."
Strategic Collaborations
Evotec maintains a strong presence in TB (搜索) drug discovery and translational science through active participation in leading global collaborations across philanthropic, non-profit and private sectors. The company is involved in key initiatives including the TB Drug Accelerator (TBDA), ERA4TB, and the PAN-TB collaboration, contributing to accelerated discovery and development of novel TB drugs and treatment regimens aimed at improving outcomes for patients worldwide.
The new grants underscore Evotec's commitment to translating innovative science into impactful therapies addressing high-priority public health threats. The company's integrated approach combines breakthrough science with AI-driven innovation and advanced technologies to accelerate the journey from concept to cure with greater precision and efficiency.